Main content 1 Menu 2 Search 3 Footer 4
+A
A
-A
High contrast
HOME JOURNAL CRITERIA NETWORK HELP ABOUT

Current criteria:

Regional:

WPRlM journal selection criteria(2023)

Minimum standards for the suspension and removal of WPRIM approved journals

Countries journal selection criteria:

Philippines

Submit your journal information>

Contact NJSCs>

Journal of Gynecologic Oncology

2002 (v1, n1) to Present ISSN: 1671-8925

Articles

About

Year of publication

Save Email

Sort by

Best match
Relevance
PubYear
JournalTitle

DISPLAY OPTIONS

Format:

Per page:

Save citations to file

Selection:

Format:

Create file Cancel

Email citations

To:

Please check your email address first!

Selection:

Format:

Send email Cancel

1635

results

page

of 164

1

Cite

Cite

Copy

Share

Share

Copy

Neoadjuvant chemotherapy followed by fertility-sparing surgery for women with stage IB1 cervical cancer.

Dan WANG ; Jiaxin YANG ; Keng SHEN ; Yang XIANG

Journal of Gynecologic Oncology.2013;24(3):287-290. doi:10.3802/jgo.2013.24.3.287

Fertility-sparing surgery was optimal to patients with tumor diameter smaller than 2 cm. For patients with larger tumors, neoadjuvant chemotherapy can debulk the tumor and offer the chance of surgery. We report 2 cases of stage IB1 cervical cancer treated by neoadjuvant chemotherapy and fertility-sparing surgery. Relevant literature was reviewed. Its safety, efficacy, and reproductive outcome need to be validated in the future.
Female ; Humans ; Uterine Cervical Neoplasms

Female ; Humans ; Uterine Cervical Neoplasms

2

Cite

Cite

Copy

Share

Share

Copy

The course of fatigue in patients with gynecologic and breast cancer.

Marie VOLLRATH ; Markus ZENGER ; Susanne SINGER ; Jens EINENKEL ; Andreas HINZ

Journal of Gynecologic Oncology.2013;24(3):280-286. doi:10.3802/jgo.2013.24.3.280

OBJECTIVE: The objective of this study is to examine the course of fatigue in female cancer patients during the first months after treatment. METHODS: We examined a sample of 110 patients suffering from gynecological or breast cancer. Fatigue was assessed with two questionnaires, the Multidimensional Fatigue Inventory (MFI) and the fatigue scale of the quality of life questionnaire European Organisation for Research and Treatment of Cancer (EORTC QLQ-C30). Participants were tested during their stay in the hospital (t1), two weeks after discharge (t2), and three months after discharge (t3). RESULTS: Fatigue in the patients' sample was markedly higher than the general population reference values. At t1, the effect sizes are d=0.81 (MFI) and d=1.21 (EORTC QLQ-C30 fatigue scale). Age and tumor stage had no significant influence on fatigue, but patients with a long time since diagnosis had higher fatigue levels than patients with a shorter time since diagnosis. From t1 to t3, fatigue mean scores decreased. The correlations between the t1 and the t3 fatigue scores were weak, with correlation coefficients of only about 0.30. CONCLUSION: Though the mean scores of fatigue, averaged across all patients, decreased over the first three months, the individual courses could not be predicted from the t1 score.
Breast ; Breast Neoplasms ; Fatigue ; Female ; Humans ; Quality of Life ; Reference Values ; Stress, Psychological ; Surveys and Questionnaires

Breast ; Breast Neoplasms ; Fatigue ; Female ; Humans ; Quality of Life ; Reference Values ; Stress, Psychological ; Surveys and Questionnaires

3

Cite

Cite

Copy

Share

Share

Copy

Selective cyclooxygenase inhibitors increase paclitaxel sensitivity in taxane-resistant ovarian cancer by suppressing P-glycoprotein expression.

Jung Pil LEE ; Ho Suap HAHN ; Soo Jin HWANG ; Ji Young CHOI ; Jong Sup PARK ; In Ho LEE ; Tae Jin KIM

Journal of Gynecologic Oncology.2013;24(3):273-279. doi:10.3802/jgo.2013.24.3.273

OBJECTIVE: The purpose of this study was to investigate whether selective cyclooxygenase (COX) inhibitors promote paclitaxel-induced apoptosis in taxane-resistant ovarian cancer cells by suppressing MDR1/P-glycoprotein (P-gp) expression. METHODS: Taxane-resistant ovarian cancer cells were cultured with paclitaxel alone or combined with a selective COX inhibitors. The expression patterns of MDR1/P-gp and the ability of COX inhibitors to inhibit growth of taxane-resistant ovarian cancer cells were measured. The efficacy of prostaglandin E2 (PGE2) supplementation was measured to evaluate the mechanisms involved in suppressing MDR1 gene expression. RESULTS: P-gp was upregulated in taxane-resistant ovarian cancer cells compared to paired paclitaxel-sensitive ovarian cancer cells. An 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay showed that selective COX inhibitors significantly enhanced the cytotoxic effects of paclitaxel in taxane-resistant ovarian cancer cells via a prostaglandin-independent mechanism. These increased apoptotic effects were further verified by measuring an increased percentage of cells in sub-G1 stage using flow cytometry. Selective COX inhibitors suppressed MDR1 and P-gp expression. Moreover, combined treatment with paclitaxel and selective COX inhibitors increased poly (ADP-ribose) polymerase (PARP) cleavage in taxane-resistant ovarian cancer cells. CONCLUSION: Selective COX inhibitors significantly promote paclitaxel-induced cell death in taxane-resistant ovarian cancer cells in a prostaglandin-independent manner. COX inhibitors could be potent therapeutic tools to promote paclitaxel sensitization of taxane-resistant ovarian cancers by suppressing MDR1/P-gp, which is responsible for the efflux of chemotherapeutic agents.
Apoptosis ; Cell Death ; Cyclooxygenase Inhibitors ; Dinoprostone ; Flow Cytometry ; Ovarian Neoplasms ; P-Glycoprotein ; Paclitaxel ; Prostaglandin-Endoperoxide Synthases ; Tetrazolium Salts ; Thiazoles

Apoptosis ; Cell Death ; Cyclooxygenase Inhibitors ; Dinoprostone ; Flow Cytometry ; Ovarian Neoplasms ; P-Glycoprotein ; Paclitaxel ; Prostaglandin-Endoperoxide Synthases ; Tetrazolium Salts ; Thiazoles

4

Cite

Cite

Copy

Share

Share

Copy

Erratum: Global cooperation in gynecologic cancer.

Edward L TRIMBLE

Journal of Gynecologic Oncology.2010;21(2):134-134. doi:10.3802/jgo.2010.21.2.134

No abstract available.

5

Cite

Cite

Copy

Share

Share

Copy

In reply: Tumor-associated lymphocytes expanded ex vivo from malignant ascites.

Shin Wha LEE ; Yong Man KIM

Journal of Gynecologic Oncology.2010;21(2):133-133. doi:10.3802/jgo.2010.21.2.133

No abstract available.
Ascites ; Lymphocytes

Ascites ; Lymphocytes

6

Cite

Cite

Copy

Share

Share

Copy

Proliferation of CD4(+)CD25(high+)Foxp3(+) regulatory T lymphocytes in ex vivo expanded ascitic fluid from primary and recurrent ovarian carcinoma.

Yong Wook JUNG ; Seok Ju SEONG ; Chong Taik PARK

Journal of Gynecologic Oncology.2010;21(2):132-132. doi:10.3802/jgo.2010.21.2.132

No abstract available.
Ascitic Fluid ; T-Lymphocytes, Regulatory

Ascitic Fluid ; T-Lymphocytes, Regulatory

7

Cite

Cite

Copy

Share

Share

Copy

Growing teratoma syndrome in a post laparoscopic excision of ovarian immature teratoma.

Anju Rani SENGAR ; Jagdeesh Narhar KULKARNI

Journal of Gynecologic Oncology.2010;21(2):129-131. doi:10.3802/jgo.2010.21.2.129

A 26-year-old girl was referred to us in December 2008 with progressive pelvic mass while on chemotherapy. In May 2008, she presented with large adnexal mass and high alpha-fetoprotein (AFP, 265.7 ng/mL; normal range, 0 to 10). She underwent laparoscopic right salpingo-oophorectomy with staging. Since histology was immature teratoma grade I, FIGO stage 1 she was kept on surveillance. In September 2008, she developed recurrent pelvic mass with AFP levels of 2,400 ng/mL. Three courses of chemotherapy (bleomycin-etoposide-cisplatin) were given. Post-chemotherapy AFP normalized but tumor size increased. CT-scan (abdomen-pelvis) showed a large pelvic mass with calcification specks; infiltrating the sigmoid colon and abdominal wall. With provisional diagnosis of growing teratoma syndrome she had exploratory laparotomy with excision of pelvic mass along with sigmoid colon, excision of right pelvic and subcutaneous deposits, omentectomy and sigmoid anastomosis. Left ovary, left tube and uterus appeared normal and were preserved. Histology of all masses showed mature teratoma, no immature elements. At six months follow up she is disease free and has resumed menstruation. Growing teratoma syndrome is a clinico-pathological presentation during/post-chemotherapy in malignant ovarian germ cell tumor where mature teratoma grows and requires complete surgical excision. Our case highlights the safety and adequacy concerns of laparoscopic management of malignant ovarian tumor. Literature review suggests good prospects of resumption of menses, child bearing and five year survival in case of growing teratoma syndrome.
Abdominal Wall ; Adult ; alpha-Fetoproteins ; Child ; Colon, Sigmoid ; Female ; Follow-Up Studies ; Humans ; Laparoscopy ; Laparotomy ; Menstruation ; Neoplasms, Germ Cell and Embryonal ; Ovary ; Reference Values ; Teratoma ; Ursidae ; Uterus

Abdominal Wall ; Adult ; alpha-Fetoproteins ; Child ; Colon, Sigmoid ; Female ; Follow-Up Studies ; Humans ; Laparoscopy ; Laparotomy ; Menstruation ; Neoplasms, Germ Cell and Embryonal ; Ovary ; Reference Values ; Teratoma ; Ursidae ; Uterus

8

Cite

Cite

Copy

Share

Share

Copy

Mullerian adenosarcoma (heterologous) of the cervix with sarcomatous overgrowth: a case report with review of literature.

Rajan DUGGAL ; Raje NIJHAWAN ; Neelam AGGARWAL ; Pooja SIKKA

Journal of Gynecologic Oncology.2010;21(2):125-128. doi:10.3802/jgo.2010.21.2.125

Mullerian adenosarcoma is a rare biphasic malignant neoplasm of the cervix characterized by an admixture of benign epithelial elements and a malignant sarcomatous stromal component, which may be either homologous or heterologous. An aggressive variant of adenosarcoma, mullerian adenosarcoma with sarcomatous overgrowth (MASO) is extremely rare, with only two such cases being reported in the English literature to date. In this report we present a case of MASO of uterine cervix with heterologous elements in a 15-year-old unmarried girl presenting with foul smelling menstrual bleeding and passage of fleshy masses. Because MASO with heterologous elements seems to appear at the earliest stages of reproductive lifespan in women, and have an uncertain malignant potential, gynecologists and pathologists should be aware and think about the possibility of this tumor.
Adenosarcoma ; Adolescent ; Cervix Uteri ; Female ; Hemorrhage ; Humans ; Single Person ; Smell

Adenosarcoma ; Adolescent ; Cervix Uteri ; Female ; Hemorrhage ; Humans ; Single Person ; Smell

9

Cite

Cite

Copy

Share

Share

Copy

Follicular stimulating hormone enhances Notch 1 expression in SK-OV-3 ovarian cancer cells.

Young Han PARK ; Su Jin KIM ; Byung Hoon JEONG ; Thomas J HERZOG ; Jason WRIGHT ; Jan KITAJEWSKI ; Chae Chun RHIM ; Pong Rheem JANG ; Jung Bae KANG ; Sung Ju KIM

Journal of Gynecologic Oncology.2010;21(2):119-124. doi:10.3802/jgo.2010.21.2.119

OBJECTIVE: Notch is known as a transmembranous receptor family with four homologous forms - Notch 1, Notch 2, Notch 3, and Notch 4 and related to cell fate regulation and angiogenesis. The purpose is to investigate the effect of follicular stimulating hormone (FSH) on the Notch 1 expression and proliferation in ovarian cancer cells. METHODS: Human ovarian cancer cell line, SK-OV-3 and FSH were used. XTT cell proliferation and cell migration assay were carried out with FSH 100 mIU/mL and Notch 1 siRNA. Western blots and reverse transcriptase-polymerase chain reactions (RT-PCR) were carried out to determine the expression level of the Notch 1 protein and mRNA with FSH treatment in 0, 1, 5, 10, 100, 200, 300 mIU/mL concentrations. Immunofluorescent (IF) stains were performed in SK-OV-3 cell cultures with FSH 100 mIU/mL. Student-t tests were used in statistical analyses. RESULTS: The SK-OV-3 have Notch 1 receptors in their natural status. FSH stimulated SK-OV-3 cells in XTT cell proliferation and cell migration assays and notch 1 siRNA inhibited. The expression level of Notch 1 protein and mRNA were increased in a dose dependent pattern according to FSH concentrations compared to untreated cells. IF stains also showed brighter Notch1 expressions in the FSH treated cells compared to the control cells. CONCLUSION: FSH enhances proliferation & migration and Notch 1 signaling in SK-OV-3 cells. The Notch signaling probably supports one of the cell proliferating mechanisms of FSH in ovarian cancer cells.
Blotting, Western ; Cell Culture Techniques ; Cell Line ; Cell Migration Assays ; Cell Proliferation ; Coloring Agents ; Humans ; Ovarian Neoplasms ; RNA, Messenger ; RNA, Small Interfering

Blotting, Western ; Cell Culture Techniques ; Cell Line ; Cell Migration Assays ; Cell Proliferation ; Coloring Agents ; Humans ; Ovarian Neoplasms ; RNA, Messenger ; RNA, Small Interfering

10

Cite

Cite

Copy

Share

Share

Copy

Wine drinking and epithelial ovarian cancer risk: a meta-analysis.

Hee Seung KIM ; Jae Weon KIM ; Leo J SHOUTEN ; Susanna C LARSSON ; Hyun Hoon CHUNG ; Yong Beom KIM ; Woong JU ; Noh Hyun PARK ; Yong Sang SONG ; Seung Cheol KIM ; Soon Beom KANG

Journal of Gynecologic Oncology.2010;21(2):112-118. doi:10.3802/jgo.2010.21.2.112

OBJECTIVE: Wine has been the focus in the prevention of epithelial ovarian cancer (EOC) development because resveratrol abundant in wine has anti-carcinogenic properties. However, epidemiologic results have been heterogenous in the chemopreventive effect of wine on the development of EOC. Thus, we performed a meta-analysis for comparing EOC risk between wine and never drinkers using previous related studies. METHODS: After extensive search of the literature between January 1986 and December 2008, we analyzed 10 studies (3 cohort and 7 case control studies) with 135,871 women, who included 65,578 of wine and 70,293 of never drinkers. RESULTS: In all studies, there was no significant difference in EOC risk between wine and never drinkers (odds ratio [OR], 1.13; 95% confidence interval [CI], 0.92 to 1.38; random effects). When we performed re-analysis according to the study design, 3 cohort and 7 case control studies showed that there were also no significant differences in EOC risk between wine and never drinkers, respectively (OR, 1.44 and 1.04; 95% CI, 0.74 and 2.82 and 0.88 to 1.22; random effects). In sub-analyses using 2 case-control studies, EOC risk was not different between former and never drinkers (OR, 1.12; 95% CI, 0.87 to 1.44; fixed effect), and between current and former drinkers (OR, 0.74; 95% CI, 0.41 to 1.34; random effects). CONCLUSION: Although resveratrol, abundantly found in wine, is a promising naturally occurring compound with chemopreventive properties on EOC in preclinical studies, this meta-analysis suggests the epidemiologic evidence shows no association between wine drinking and EOC risk.
Case-Control Studies ; Cohort Studies ; Drinking ; Female ; Humans ; Neoplasms, Glandular and Epithelial ; Ovarian Neoplasms ; Stilbenes ; Wine

Case-Control Studies ; Cohort Studies ; Drinking ; Female ; Humans ; Neoplasms, Glandular and Epithelial ; Ovarian Neoplasms ; Stilbenes ; Wine

Country

Republic of Korea

Publisher

Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology

ElectronicLinks

http://synapse.koreamed.org/LinkX.php?code=1114JGO

Editor-in-chief

E-mail

Abbreviation

J Gynecol Oncol

Vernacular Journal Title

부인종양

ISSN

2005-0380

EISSN

2005-0399

Year Approved

2007

Current Indexing Status

Currently Indexed

Start Year

Description

Previous Title

Korean Journal of Gynecologic Oncology
Korean Journal of Gynecologic Oncology and Colposcopy

Related Sites

WHO WPRO GIM

Help Accessibility
DCMS Web Policy
CJSS Privacy Policy

Powered by IMICAMS( 备案号: 11010502037788, 京ICP备10218182号-8)

Successfully copied to clipboard.